Chr. Hansen experienced a strong second quarter and maintains the outlook for the year
“Following a strong Q2 with 10% organic growth and solid margin development we remain on track to deliver on our outlook for the full year, expecting organic revenue growth of 7-9% and an EBIT margin before special items above 26%,” says CEO Cees de Jong.
“We have continued to implement our Nature’s No. 1 strategy with initiatives to support the future growth and profitability of Chr. Hansen. I am especially pleased with the good performance of both the Cultures & Enzymes Division and the EMEA region in general as well as to see the first sales of cultures for crop protection.”
Highlights first half 2013/14
- Revenue EUR 353 million, unchanged from first half 2012/13
- Organic growth 6%
- EBIT before special items and impairments EUR 88 million and EBIT margin before special items and impairments 25.0%, both unchanged from last year
Second quarter 2013/14 results
- Revenue EUR 182 million, up 4% on last year
- Organic growth 10%
- EBIT margin before special items and impairments 24.8%, up from 23.3% last year
Outlook for 2013/14
The outlook for 2013/14 is unchanged from the announcement of 15 January 2014.
Organic revenue growth is expected to be 7‐9%.
The EBIT margin before special items is expected to be above 26%.
Full interim report
Please see the interim report for further details:
Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2013/14 financial year was EUR 756 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,500 dedicated employees in over 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on NASDAQ OMX Copenhagen.